rhEGF 凝胶对面部激素依赖性皮炎皮肤功能改善的临床研究

摘要： 目的 研究重组人表皮生长因子（rhEGF）凝胶联合他克莫司治疗面部激素依赖性皮炎的临床效果， 并观察其对皮肤功能的影响及复发情况。方法 将 48 例面部激素依赖性皮炎门诊患者随机分为治疗组 （rhEGF 凝胶联合他克莫司） 和对照组 （单用他克莫司）， 每组 24 例。于治疗前、 治疗 4 周后门诊复诊时测定患者面部皮损处表皮含水量、 油脂及经皮水分丢失 （TEWL）； 于治疗后第 1、 2、 4 周按照湿疹皮炎严重指数评分 （EASI） 法计算疗效指数， 治疗期间观察患者不良反应及复发情况等。结果 与治疗前相比， 治疗 4 周后治疗组和对照组皮损表皮含水量、 油脂均升高， TEWL 降低 （均 P＜0.05）， 治疗前、 后 2 组间差异均无统计学意义。治疗 1 周治疗组总显效率与对照组差异无统计学意义（45.8% vs. 20.8%， P＞0.05）， 治疗 2、 4 周时， 治疗组总显效率均高于对照组（79.2% vs. 50.0%， 91.2% vs. 62.5%， 均 P＜0.05）。治疗组治疗过程中均未出现不良反应， 且其复发率明显低于对照组 （12.5% vs. 37.5%， χ2=4.03， P＜0.05）。结论 rhEGF 凝胶对面部激素依赖性皮炎有较好的辅助治疗效果， 可显著改善皮肤功能， 且复发率低。

Clinical study on the efficiency of rhEGF gel to skin function of facial hormone-dependent dermatitis

Abstract:Objective To study the clinical effects of recombinant human epidermal growth factor (rhEGF) gel combined with tacrolimus treatment on facial hormone-dependent dermatitis, and to investigate its influence in skin function and recurrence of dermatitis. Methods Forty-eight outpatients with facial hormone-dependent dermatitis were randomly divided into treatment group (n=24, treatment with tacrolimus combined rhEGF gel) and control group (n=24, treatment with tacrolimus). The moisture of skin, sebum content and transepidermal water loss (TEWL) were examined before treatment and 4 weeks after treatment in two groups. Eczema area and severity index (EASI) were calculated at 1 week, 2 weeks and 4 weeks after treatment. The adverse reactions and recurrence of dermatitis were observed during the treatment as well. Results Compared with pre-treatment, the moisture of skin and sebum content were increased (P＜0.05) and the TEWL was decreased (P＜0.05) after 4-week treatment. The differences were not statistically significant between two groups. The obvious effective rate of the treatment group (45.8%) was not significantly different from that of the control group (20.8%) after 1 week of treatment (P＞0.05), but it is much higher in treatment group after two-week treatment (79.2% vs. 50.0%, P＜ 0.05) and after four- week treatment (91.2% vs. 62.5% , P＜0.05). Furthermore, there was no adverse reaction in the treatment group, and the recurrence rate was much lower in treatment group (12.5%) than that of the control group (37.5%, 2χ =4.03， P＜0.05). Conclusion Recombinant human epidermal growth factor gel has an auxiliary curative effect on facial hormone-dependent dermatitis and can significantly improve skin function, and the recurrence rate of dermatitis is low.